Cancer diagnostics group VolitionRx Limited (NYSE:VNRX) has commenced its first triage products study in Asia, while in Europe it has received ethical approval to proceed with the second and final phase for a triage study in Denmark.
In a statement, the NYSE-listed firm said it has begun an evaluation of its Nu.QTM Colorectal Cancer Triage product in a Taiwanese population of 383 subjects.
The study is being conducted with Professor Chiu Han-Mo of the National Taiwan University Hospital and is expected to be completed within the coming months.
Dr Jasmine Kway, Volition's Vice President of Asia said: "We are pleased to be working with Professor Chiu Han-Mo and hope to develop a long-term working relationship.”
'This is an exciting time for Volition as we start our first clinical work in Asia. In addition, we are also taking our first regulatory steps in Asia as we prepare the submission of our CE Marked Nu.QTM Triage product to the Singapore and Taiwan regulatory authorities.
“Regulatory approval in Singapore and Taiwan would not only make our product saleable in these countries but also potentially in nine other South East Asian markets."
Ethical approval for final phase of Nu.QTM Triage Test in Denmark
Meanwhile, in Europe, Volition said it has received ethical approval to proceed with the second and final phase of the logistics and pathway design study for its Nu.QTM Triage Test in Denmark.
The study, conducted in collaboration with the Hvidovre Hospital and The Danish Research Group on Early Detection of Colorectal Cancer, deals with the practical issues of how the product fits into Denmark's current national screening program.
The group said results from the study are expected by the end of the third quarter this year and will be presented to the National Screening Committee.
Volition's chief marketing and communications officer, Louise Day commented: "We are delighted to receive this timely Ethical Approval for the second phase of the logistics and pathway study.
“We are hopeful that our collaborators in Denmark will determine the very practical logistics of putting into practice the Nu.QTM Triage Test and provide a smooth, patient-friendly implementation into the Screening Program."